Literature DB >> 12771131

Repressors of androgen and progesterone receptor action.

Irina U Agoulnik1, William C Krause, William E Bingman, Hassan T Rahman, Mojghan Amrikachi, Gustavo E Ayala, Nancy L Weigel.   

Abstract

Androgen and progesterone receptors (AR and PR) are two determining factors in gonadal differentiation that are highly expressed in developing and mature gonads. Loss of AR results in XY sex reversal and mutations causing reduced AR activity lead to varying degrees of defects in masculinization. Female PR knockout mice are infertile due to ovarian defects. While much has been discovered about positive regulation of these receptors by coactivators little is known about repression of the transcriptional activity of AR and PR in the presence of agonists. In this study we assessed the effect of SMRT and DAX-1 on AR and PR activity in the presence of both agonists and partial antagonists. We show that SMRT and DAX-1 repress agonist-dependent activity of both receptors, and the mechanism of repression includes disruption of the receptor dimer interactions rather than recruitment of histone deacetylases. We demonstrate that endogenous agonist-bound PR and DAX-1 in T47D breast cancer cells and endogenous AR and DAX-1 in LNCaP prostate cancer cells can be coimmunoprecipitated suggesting that the interaction is physiological. Surprisingly, although DAX-1 represses partial antagonist activity of AR, it was ineffective in repressing partial antagonist induced activity of PR. In contrast to most reported repressors, the expression of DAX-1 is restricted. We found that although DAX-1 is expressed in normal human prostate, its expression is strongly reduced in benign prostatic hyperplasia suggesting that DAX-1 plays a role in limiting AR activity in prostate.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12771131     DOI: 10.1074/jbc.M305153200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  42 in total

1.  Proteomic analyses to identify novel therapeutic targets for the treatment of advanced prostate cancer.

Authors:  Barbara Comuzzi; Marianne D Sadar
Journal:  Cellscience       Date:  2006-07-27

Review 2.  Androgens and estrogens in benign prostatic hyperplasia: past, present and future.

Authors:  Tristan M Nicholson; William A Ricke
Journal:  Differentiation       Date:  2011-05-26       Impact factor: 3.880

Review 3.  Hypogonadotropic hypogonadism in subjects with DAX1 mutations.

Authors:  Unmesh Jadhav; Rebecca M Harris; J Larry Jameson
Journal:  Mol Cell Endocrinol       Date:  2011-06-13       Impact factor: 4.102

4.  Cloning, characterization and function analysis of DAX1 in Chinese loach (Paramisgurnus dabryanus).

Authors:  Xiaohua Xia; Weiran Huo; Ruyan Wan; Peijin Wang; Zhongjie Chang
Journal:  Genetica       Date:  2018-09-11       Impact factor: 1.082

5.  Expression of ERG protein in prostate cancer: variability and biological correlates.

Authors:  Gustavo Ayala; Anna Frolov; Deyali Chatterjee; Dandan He; Susan Hilsenbeck; Michael Ittmann
Journal:  Endocr Relat Cancer       Date:  2015-06       Impact factor: 5.678

6.  Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression.

Authors:  Ayesha A Shafi; Marc B Cox; Nancy L Weigel
Journal:  Steroids       Date:  2013-02-01       Impact factor: 2.668

7.  Progesterone receptor B recruits a repressor complex to a half-PRE site of the estrogen receptor alpha gene promoter.

Authors:  F De Amicis; S Zupo; M L Panno; R Malivindi; F Giordano; I Barone; L Mauro; S A W Fuqua; S Andò
Journal:  Mol Endocrinol       Date:  2009-01-15

8.  Dax-1 and steroid receptor RNA activator (SRA) function as transcriptional coactivators for steroidogenic factor 1 in steroidogenesis.

Authors:  Bin Xu; Wei-Hsiung Yang; Isabelle Gerin; Chang-Deng Hu; Gary D Hammer; Ronald J Koenig
Journal:  Mol Cell Biol       Date:  2009-02-02       Impact factor: 4.272

9.  Inhibition of cyclin D1 expression by androgen receptor in breast cancer cells--identification of a novel androgen response element.

Authors:  Marilena Lanzino; Diego Sisci; Catia Morelli; Cecilia Garofalo; Stefania Catalano; Ivan Casaburi; Claudia Capparelli; Cinzia Giordano; Francesca Giordano; Marcello Maggiolini; Sebastiano Andò
Journal:  Nucleic Acids Res       Date:  2010-04-26       Impact factor: 16.971

10.  ARF represses androgen receptor transactivation in prostate cancer.

Authors:  Wenfu Lu; Yingqiu Xie; Yufang Ma; Robert J Matusik; Zhenbang Chen
Journal:  Mol Endocrinol       Date:  2013-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.